Clinical Experience with Intravenous Estramustine Phosphate, Paclitaxel, and Carboplatin in Patients with Castrate, Metastatic Prostate Adenocarcinoma
Antineoplastic Combined Chemotherapy Protocols
Intravenous EMP was administered safely with paclitaxel and carboplatin and produced clinical outcomes similar to the outcomes achieved with the TEC regimen. Substitution of i.v. EMP for the oral formulation was found to result in a lower incidence of severe nausea but increased hepatic toxicity.